Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma

Novel combination therapies have markedly improved the lifespan of patients with multiple myeloma (MM), but drug resistance and disease relapse remain major clinical problems. Dexamethasone and other glucocorticoids are a cornerstone of conventional and new combination therapies for MM, although the...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Spaan, Ingrid, Timmerman, Laura M., Kimman, Thomas, Slomp, Anne, Cuenca, Marta, van Nieuwenhuijzen, Niels, Moesbergen, Laura M., Minnema, Monique C., Raymakers, Reinier A., Peperzak, Victor
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2021
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270664/
https://ncbi.nlm.nih.gov/pubmed/34152396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003624
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak